Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...

(HealthDay News) — For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic cough, according to a study published online ...

Wellgistics Health Inc ( ($WGRX) ) has issued an update. On December 8, 2025, Wellgistics Health, Inc. announced the commercial launch of its ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...

Women with diabetes can achieve healthy pregnancies with meticulous preparation. Experts emphasize achieving stable blood ...

The risk of sudden cardiac death is higher for people with both type 1 and type 2 diabetes, according to a large study ...

People with either type 1 or type 2 diabetes have a dramatically higher risk of sudden cardiac death, which occurs when the ...

Investing.com -- Wellgistics Health Inc (NASDAQ:WGRX) stock surged 9.2% on Monday after the health information technology company announced the commercial launch of diabetes prescription drug ...

Resmetirom effectively resolves MASH and improves fibrosis, independent of GLP-1 or SGLT2 inhibitor use, in patients with T2DM. Achieving ≥5% weight loss enhances resmetirom's effects on MASH ...

Novo Nordisk's amycretin cut A1C and body weight in a phase 2 study, with no plateau seen, as the company targets a 2026 ...